Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I.

Nat Med. 2019 Feb 11. doi: 10.1038/s41591-018-0339-5. [Epub ahead of print]

PMID:
30742120
2.

TGFβ blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies.

Rodriguez-Ruiz ME, Rodriguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, Ponz-Sarvise M, Azpilikueta A, Bolaños E, Sanmamed MF, Berraondo P, Calvo FA, Barcellos-Hoff MH, Perez-Gracia JL, Melero I.

Mol Cancer Ther. 2019 Jan 25. pii: molcanther.0558.2018. doi: 10.1158/1535-7163.MCT-18-0558. [Epub ahead of print]

PMID:
30683810
3.

A new immune-nanoplatform for promoting adaptive antitumor immune response.

Merino M, Contreras A, Casares N, Troconiz IF, Ten Hagen TL, Berraondo P, Zalba S, Garrido MJ.

Nanomedicine. 2019 Jan 14;17:13-25. doi: 10.1016/j.nano.2018.12.016. [Epub ahead of print]

PMID:
30654186
4.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

PMID:
30413827
5.

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.

Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, Pejenaute Á, Kalariya M, Butcher W, Park JS, Zhu X, Sabnis S, Kumarasinghe ES, Salerno T, Kenney M, Lukacs CM, Ávila MA, Martini PGV, Fontanellas A.

Nat Med. 2018 Dec;24(12):1899-1909. doi: 10.1038/s41591-018-0199-z. Epub 2018 Oct 8.

PMID:
30297912
6.

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.

Sánchez-Paulete AR, Teijeira Á, Quetglas JI, Rodríguez-Ruiz ME, Sánchez-Arráez Á, Labiano S, Etxeberria I, Azpilikueta A, Bolaños E, Ballesteros-Briones MC, Casares N, Quezada SA, Berraondo P, Sancho D, Smerdou C, Melero I.

Cancer Res. 2018 Dec 1;78(23):6643-6654. doi: 10.1158/0008-5472.CAN-18-0933. Epub 2018 Oct 8.

PMID:
30297531
7.

An RNA toolbox for cancer immunotherapy.

Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I.

Nat Rev Drug Discov. 2018 Oct;17(10):751-767. doi: 10.1038/nrd.2018.132. Epub 2018 Sep 7. Review.

PMID:
30190565
8.

International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.

Berraondo P, Aznar MA, Perez-Ruiz E, Rodriguez-Ruiz ME, Castañon E, Perez-Gracia JL, Melero I.

Cancer Immunol Immunother. 2018 Nov;67(11):1809-1813. doi: 10.1007/s00262-018-2240-y. Epub 2018 Sep 4. No abstract available.

PMID:
30182281
9.

Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.

Serrano-Mendioroz I, Sampedro A, Serna N, de Salamanca RE, Sanz-Parra A, Corrales F, Berraondo P, Millet O, Fontanellas A.

Hum Mol Genet. 2018 Nov 1;27(21):3688-3696. doi: 10.1093/hmg/ddy283.

PMID:
30085095
10.

Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy.

Etxeberria I, Teijeira A, Montuenga LM, Berraondo P, Melero I.

Cancer Discov. 2018 Jul;8(7):794-796. doi: 10.1158/2159-8290.CD-18-0573.

PMID:
29967073
11.

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.

Ann Oncol. 2018 May 1;29(5):1312-1319. doi: 10.1093/annonc/mdy089.

PMID:
29554212
12.

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I.

Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

PMID:
29549160
13.

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P.

Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

14.

New trends in antitumor vaccines in melanoma.

Vasquez M, Tenesaca S, Berraondo P.

Ann Transl Med. 2017 Oct;5(19):384. doi: 10.21037/atm.2017.09.09. Review.

15.

An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.

Serrano-Mendioroz I, Sampedro A, Alegre M, Enríquez de Salamanca R, Berraondo P, Fontanellas A.

Hum Gene Ther. 2018 Apr;29(4):480-491. doi: 10.1089/hum.2017.056. Epub 2018 Jan 2.

PMID:
28990424
16.

Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice.

Alvarez-Sola G, Uriarte I, Latasa MU, Jimenez M, Barcena-Varela M, Santamaría E, Urtasun R, Rodriguez-Ortigosa C, Prieto J, Corrales FJ, Baulies A, García-Ruiz C, Fernandez-Checa JC, Berraondo P, Fernandez-Barrena MG, Berasain C, Avila MA.

Cell Death Dis. 2017 Oct 5;8(10):e3083. doi: 10.1038/cddis.2017.480.

17.

Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications.

Alvarez-Sola G, Uriarte I, Latasa MU, Jimenez M, Barcena-Varela M, Santamaría E, Urtasun R, Rodriguez-Ortigosa C, Prieto J, Berraondo P, Fernandez-Barrena MG, Berasain C, Avila MA.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1326-1334. doi: 10.1016/j.bbadis.2017.06.025. Epub 2017 Jul 12. Review.

PMID:
28709961
18.

Cellular immunotherapies for cancer.

Berraondo P, Labiano S, Minute L, Etxeberria I, Vasquez M, Sanchez-Arraez A, Teijeira A, Melero I.

Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619. eCollection 2017. Review.

19.

Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1.

Vasquez M, Simões I, Consuegra-Fernández M, Aranda F, Lozano F, Berraondo P.

Eur J Immunol. 2017 Jul;47(7):1108-1118. doi: 10.1002/eji.201646903. Epub 2017 Jun 12. Review.

20.

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy.

Garrido MJ, Berraondo P, Trocóniz IF.

CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):277. doi: 10.1002/psp4.12186. Epub 2017 Apr 6. No abstract available.

21.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
22.

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P.

Immunol Cell Biol. 2017 Apr;95(4):347-355. doi: 10.1038/icb.2017.6. Epub 2017 Feb 21. Review.

PMID:
28138156
23.

Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.

Alvarez-Sola G, Uriarte I, Latasa MU, Fernandez-Barrena MG, Urtasun R, Elizalde M, Barcena-Varela M, Jiménez M, Chang HC, Barbero R, Catalán V, Rodríguez A, Frühbeck G, Gallego-Escuredo JM, Gavaldà-Navarro A, Villarroya F, Rodriguez-Ortigosa CM, Corrales FJ, Prieto J, Berraondo P, Berasain C, Avila MA.

Gut. 2017 Oct;66(10):1818-1828. doi: 10.1136/gutjnl-2016-312975. Epub 2017 Jan 24.

PMID:
28119353
24.

Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model.

Vasquez M, Paredes-Cervantes V, Aranda F, Ardaiz N, Gomar C, Berraondo P.

Oncotarget. 2017 Jan 17;8(3):5247-5255. doi: 10.18632/oncotarget.14127.

25.

Commentary on Pharmacometrics for Immunotherapy.

Garrido MJ, Berraondo P, Trocóniz IF.

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):8-10. doi: 10.1002/psp4.12162. Epub 2017 Jan 17. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):277.

26.

Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy.

Melero I, Berraondo P, Rodríguez-Ruiz ME, Pérez-Gracia JL.

Cancer Discov. 2016 Dec;6(12):1312-1314.

27.

Emerging therapies for acute intermittent porphyria.

Fontanellas A, Ávila MA, Berraondo P.

Expert Rev Mol Med. 2016 Nov 2;18:e17. Review.

PMID:
27804912
28.

Innate immune mediators in cancer: between defense and resistance.

Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R.

Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464. Review.

PMID:
27782320
29.

Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.

Contreras-Sandoval AM, Merino M, Vasquez M, Trocóniz IF, Berraondo P, Garrido MJ.

Oncotarget. 2016 Nov 22;7(47):76891-76901. doi: 10.18632/oncotarget.12727.

30.

Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function.

Vasquez M, Fioravanti J, Aranda F, Paredes V, Gomar C, Ardaiz N, Fernandez-Ruiz V, Méndez M, Nistal-Villan E, Larrea E, Gao Q, Gonzalez-Aseguinolaza G, Prieto J, Berraondo P.

Oncoimmunology. 2016 Jun 29;5(8):e1196309. doi: 10.1080/2162402X.2016.1196309. eCollection 2016 Aug.

31.

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.

Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I.

Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.

32.

Cancer Immunosurveillance Caught in the Act.

Berraondo P, Teijeira A, Melero I.

Immunity. 2016 Mar 15;44(3):525-526. doi: 10.1016/j.immuni.2016.03.004.

33.

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, Garasa S, Fusco JP, Aznar A, Inogés S, De Pizzol M, Allegretti M, Medina-Echeverz J, Berraondo P, Perez-Gracia JL, Melero I.

Clin Cancer Res. 2016 Aug 1;22(15):3924-36. doi: 10.1158/1078-0432.CCR-15-2463. Epub 2016 Mar 8.

34.

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.

Labiano S, Palazón A, Bolaños E, Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, Aznar MA, Jure-Kunkel M, Berraondo P, Melero I.

Oncoimmunology. 2015 Jun 24;5(1):e1062967. eCollection 2016.

35.

Immunological Landscape and Clinical Management of Rectal Cancer.

Pérez-Ruiz E, Berraondo P.

Front Immunol. 2016 Feb 22;7:61. doi: 10.3389/fimmu.2016.00061. eCollection 2016. Review.

36.

Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.

Medina-Echeverz J, Vasquez M, Gomar C, Ardaiz N, Berraondo P.

Cancer Immunol Immunother. 2015 Jun;64(6):717-25. doi: 10.1007/s00262-015-1681-9. Epub 2015 Mar 21.

PMID:
25795134
37.

Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I.

Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J, Kallakury BV, Tucker RD, Vasquez M, Menne S, Prieto J, González-Aseguinolaza G.

J Hepatol. 2015 Aug;63(2):329-36. doi: 10.1016/j.jhep.2015.02.048. Epub 2015 Mar 12.

38.

Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice.

Di Scala M, Gil-Fariña I, Vanrell L, Sánchez-Bayona R, Alignani D, Olagüe C, Vales A, Berraondo P, Prieto J, González-Aseguinolaza G.

Haematologica. 2015 Aug;100(8):1014-22. doi: 10.3324/haematol.2014.115410. Epub 2015 Feb 24.

39.

Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization.

Domínguez-Soto A, de las Casas-Engel M, Bragado R, Medina-Echeverz J, Aragoneses-Fenoll L, Martín-Gayo E, van Rooijen N, Berraondo P, Toribio ML, Moro MA, Cuartero I, Castrillo A, Sancho D, Sánchez-Torres C, Bruhns P, Sánchez-Ramón S, Corbí AL.

J Immunol. 2014 Nov 15;193(10):5181-9. doi: 10.4049/jimmunol.1303375. Epub 2014 Oct 17.

40.

Myeloid-derived cells are key targets of tumor immunotherapy.

Medina-Echeverz J, Aranda F, Berraondo P.

Oncoimmunology. 2014 Apr 15;3:e28398. eCollection 2014. Review.

41.

Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases.

Medina-Echeverz J, Fioravanti J, Díaz-Valdés N, Frank K, Aranda F, Gomar C, Ardaiz N, Dotor J, Umansky V, Prieto J, Berraondo P.

PLoS One. 2014 May 5;9(5):e96799. doi: 10.1371/journal.pone.0096799. eCollection 2014.

42.

Modeling tumor response after combined administration of different immune-stimulatory agents.

Parra-Guillen ZP, Berraondo P, Ribba B, Trocóniz IF.

J Pharmacol Exp Ther. 2013 Sep;346(3):432-42. doi: 10.1124/jpet.113.206961. Epub 2013 Jul 11.

PMID:
23845890
43.

High-density lipoproteins delivering interleukin-15.

Ochoa MC, Melero I, Berraondo P.

Oncoimmunology. 2013 Apr 1;2(4):e23410.

44.

Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Parra-Guillen ZP, Berraondo P, Grenier E, Ribba B, Troconiz IF.

AAPS J. 2013 Jul;15(3):797-807. doi: 10.1208/s12248-013-9483-5. Epub 2013 Apr 19.

45.

Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives.

Hernandez-Alcoceba R, Sangro B, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J.

Expert Opin Investig Drugs. 2013 Jul;22(7):827-41. doi: 10.1517/13543784.2013.793307. Epub 2013 Apr 18. Review.

PMID:
23594171
46.

Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses.

Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-Guillen M, Casales E, Medina-Echeverz J, Prieto J, Berraondo P, Hervas-Stubbs S, Smerdou C.

J Immunol. 2013 Mar 15;190(6):2994-3004. doi: 10.4049/jimmunol.1201791. Epub 2013 Feb 11.

47.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

48.

How can chemoimmunotherapy best be used for the treatment of colon cancer?

Medina-Echeverz J, Berraondo P.

Immunotherapy. 2012 Dec;4(12):1787-90. doi: 10.2217/imt.12.124. No abstract available.

49.

Interleukin-15 in gene therapy of cancer.

Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I.

Curr Gene Ther. 2013 Feb;13(1):15-30. Review.

PMID:
23157547
50.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.

Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13.

Supplemental Content

Loading ...
Support Center